title: The potential of soluble epoxide hydrolase inhibition in the treatment of cardiac hypertrophy.
authors.affiliation: Department of Entomology and Cancer Center, University of California, Davis, CA 95616, USA.
authors.forename: Todd R
authors.initials: TR
authors.lastname: Harris
authors.forename: Ning
authors.initials: N
authors.lastname: Li
authors.forename: Nipanvan
authors.initials: N
authors.lastname: Chiamvimonvat
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Hammock
mesh_terms: D006332:Cardiomegaly / Q000188:drug therapy*; D004727:Endothelium / Q000187:drug effects; D004851:Epoxide Hydrolases / Q000037:antagonists & inhibitors*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D004851:Epoxide Hydrolases
references.citation: Circ Res. 2002 Nov 1;91(9):776-81
references.pmid: 12411391
references.citation: J Biol Chem. 2001 Oct 5;276(40):37621-9
references.pmid: 11448959
references.citation: Cardiovasc Drug Rev. 2006 Summer;24(2):169-88
references.pmid: 16961727
references.citation: Am J Physiol Renal Physiol. 2005 Sep;289(3):F496-503
references.pmid: 16093425
references.citation: Circulation. 2004 Apr 6;109(13):1580-9
references.pmid: 15066961
references.citation: Am J Med Sci. 2003 Jul;326(1):15-24
references.pmid: 12861121
references.citation: J Biol Chem. 1998 Apr 3;273(14):8232-9
references.pmid: 9525929
references.citation: Oncogene. 1999 Nov 22;18(49):6867-74
references.pmid: 10602462
references.citation: Cell. 1996 Oct 4;87(1):13-20
references.pmid: 8858144
references.citation: J Pharmacol Exp Ther. 1995 Aug;274(2):798-804
references.pmid: 7636743
references.citation: Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):42-9
references.pmid: 17164131
references.citation: Circulation. 2004 Mar 16;109(10):1196-205
references.pmid: 15023894
references.citation: Annu Rev Pharmacol Toxicol. 2005;45:311-33
references.pmid: 15822179
references.citation: J Cardiovasc Pharmacol. 2007 Sep;50(3):225-37
references.pmid: 17878749
references.citation: Am J Physiol Cell Physiol. 2007 Mar;292(3):C996-1012
references.pmid: 16987999
references.citation: Science. 2001 Nov 30;294(5548):1871-5
references.pmid: 11729303
references.citation: Biochem Pharmacol. 2004 Apr 15;67(8):1445-57
references.pmid: 15041462
references.citation: Circulation. 2002 Jan 1;105(1):85-92
references.pmid: 11772881
references.citation: Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18733-8
references.pmid: 17130447
references.citation: FASEB J. 1992 Jan 6;6(2):731-6
references.pmid: 1537463
references.citation: Heart Fail Rev. 2001 Mar;6(2):129-36
references.pmid: 11309531
references.citation: Circulation. 2002 Jan 29;105(4):509-15
references.pmid: 11815436
references.citation: Nat Immunol. 2002 Mar;3(3):221-7
references.pmid: 11875461
references.citation: Clin Exp Pharmacol Physiol. 2004 Sep;31(9):650-5
references.pmid: 15479174
references.citation: Prog Lipid Res. 2005 Jan;44(1):1-51
references.pmid: 15748653
references.citation: J Mol Cell Cardiol. 2000 Oct;32(10):1767-78
references.pmid: 11013121
references.citation: Circulation. 2003 Aug 12;108(6):638-40
references.pmid: 12912791
references.citation: J Cell Biol. 2002 Dec 23;159(6):1019-28
references.pmid: 12486112
references.citation: Basic Res Cardiol. 2007 Jul;102(4):279-97
references.pmid: 17530315